Current research studies are actively investigating the viability of combination strategies as a means of converting MSS “cold tumor” into an immune-responsive “hot tumor.” Although the combination of ICIs with chemotherapy, bevacizumab, cetuximab, and Mitogen-Activated Protein Kinase Kinase (MEK) inhibitor has been investigated in some clinical trials, these studies failed to show a significant improvement in ORR, PFS, or OS with this combination (15–18). This evidence concerns the gene WNK2 and neoplasm.